News: Pacira Pharmaceuticals Inc (PCRX.OQ)
PCRX.OQ on NASDAQ Stock Exchange Global Select Market
34.05USD
11:00am EDT
34.05USD
11:00am EDT
Price Change (% chg)
$-0.06 (-0.18%)
$-0.06 (-0.18%)
Prev Close
$34.11
$34.11
Open
$31.00
$31.00
Day's High
$34.92
$34.92
Day's Low
$30.75
$30.75
Volume
130,711
130,711
Avg. Vol
116,882
116,882
52-wk High
$35.86
$35.86
52-wk Low
$14.46
$14.46
Select another date:
Thu, Aug 1 2013
Pacira Pharma pain drug fails late-stage trial
- Pacira Pharmaceuticals Inc said its lead drug did not meet the main goal in a late-stage trial of reducing pain for patients undergoing a surgical procedure called posterolateral thoracotomy.
Select another date:
- Here's Why Pacira Pharmaceuticals's Latest Report Might Worry You
- 2 Healthcare Companies With Recent Intensive Insider Selling
- FDA Accepts New Drug Application And Creates A Catalyst For Durect Corporation
- 5 Buy Signals From the Health Care Sector
- SALT 2013: The 5 Best Ideas of the Year Ahead
- Pacira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Press Releases
- New Publication Suggests Higher Opioid Use in the Postsurgical Setting May Be Linked to Extended Hospital Stay and Increased Cost of Care
- Pacira Pharmaceuticals, Inc. and Aratana Therapeutics Inc. Enter into Global Licensing Agreement for Development and Commercialization of Bupivacaine Liposome Injectable Suspension for Animal Health Indications
- New Data Demonstrate Reduction in Opioid Use, Hospital Cost and Length of Stay with EXPAREL as the Foundation of a Multimodal Regimen
- Pacira Pharmaceuticals, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
- New Data Supporting Use of EXPAREL via Infiltration into the Transversus Abdominis Plane Presented at 11th Annual American Society of Regional Anesthesia and Pain Medicine Meeting
- Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
- Pacira Pharmaceuticals, Inc. Reports $4.6 Million in Third Quarter EXPAREL Revenue and Full Third Quarter 2012 Financial Results
- Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
- Richard A. Baxter, M.D., Receives OR Excellence Award for Use of EXPAREL®
- EXPAREL® as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay

